Paid Clinical Trials Savannah
Discover 197 paid clinical trials in Savannah, Georgia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Randomized Trial Comparing Immediate Vs. Deferred Surgery for Symptomatic ERM
Sponsor:
Jaeb Center for Health Research
Location:
Code:
NCT05145491
Conditions
Epiretinal Membrane
Eligibility Criteria
Sex: All
Age: 50+
Healthy Volunteers: Not accepted
Interventions
Immediate Vitrectomy
Deferred Vitrectomy
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT04396574
Conditions
Migraine
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Lasmiditan
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Sponsor:
Uniquity One (UNI)
Location:
Code:
NCT06496620
Conditions
COPD
Eligibility Criteria
Sex: All
Age: 40 - 70
Healthy Volunteers: Not accepted
Interventions
Biological: Solrikitug low dose
Biological: Solrikitug high dose
Placebo
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05256225
Conditions
Endometrial Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Dedifferentiated Carcinoma
Endometrial Endometrioid Adenocarcinoma
Endometrial Mixed Cell Adenocarcinoma
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Carboplatin
Computed Tomography
Echocardiography
High-Dose-Rate Vaginal Cuff Brachytherapy
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
Sponsor:
Neumora Therapeutics, Inc.
Location:
Code:
NCT06429722
Conditions
Major Depressive Episode Associated With Bipolar II Disorder
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
NMRA-335140 80 mg
Placebo
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT05147220
Conditions
Relapsing Multiple Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Not accepted
Interventions
Remibrutinib
Teriflunomide
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria
Sponsor:
Evommune, Inc.
Location:
Code:
NCT06603220
Conditions
Chronic Inducible Urticaria
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
Oral EVO756
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sponsor:
Sanofi
Location:
Code:
NCT06141473
Conditions
Multiple Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Not accepted
Interventions
Frexalimab
Teriflunomide
Placebo infusion
Placebo tablet
MRI contrast-enhancing agents
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Sponsor:
NRG Oncology
Location:
Code:
NCT05095376
Conditions
Glioblastoma
Gliosarcoma
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Lomustine
Photon Beam Radiation Therapy
Quality-of-Life Assessment
Questionnaire Administration
Temozolomide